Navigation Links
Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
Date:9/12/2012

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from the University of California to commercialize an invention for expanding pancreatic islets.

"In the course of research conducted at the University of California, Los Angeles, Dr. Anil Bhushan and Dr. Sangeeta Dhawan have developed a technology entitled 'small molecules for islet expansion,'" stated Dr. Jonathan Lakey, Islet Sciences Chief Scientific Officer. "We are pleased to work with UCLA in bringing this promising technology to the next level as we look to commercialize it to benefit the growing worldwide diabetic community."

John Steel, Chairman and CEO of Islet Sciences commented, "The company is pleased to add to its expanding diabetes franchise with complimentary technologies."

About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. www.isletsciences.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson, ProActive Capital Group
(646) 863-6893 
jramson@proactivecrg.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
2. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
3. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
4. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
5. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
6. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
7. Life Technologies to Present at UBS Global Life Sciences Conference
8. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
9. Life Sciences Venture Capital Funding Shrinks for Fourth Straight Quarter According to the MoneyTree Report
10. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
11. NSBRI Renews Space Life Sciences Graduate Programs at MIT, Texas A&M
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office (EPO) ... one of three finalists for the European Inventor Award 2016 in the category "Non-European ... be announced at a ceremony in Lisbon on June 9th. , The human capacity ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... Mr. Palmer ... Adecco RPO, signing the first multi-million dollar, multi-year managed services contract in the U.S. ... have Michael join our leadership team,” said John Younger, founder of Accolo. “We ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... BioFactura, ... $1.8M Series A round of financing. Healthy investor interest drove significant oversubscription of ... of generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive ...
(Date:4/26/2016)... Hungary , VIENNA ... 2016 The prize recognizes ... the resulting revolutionary innovations that will benefit patients ... http://photos.prnewswire.com/prnh/20160210/331945LOGO ) , ... novel proprietary trend setting products in the field ...
Breaking Biology Technology:
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
(Date:3/2/2016)... 2, 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ... as a Service Market 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ...
Breaking Biology News(10 mins):